CRNX
Price
$30.99
Change
+$0.58 (+1.91%)
Updated
Jul 25 closing price
Capitalization
2.9B
12 days until earnings call
ZYME
Price
$13.33
Change
-$0.68 (-4.85%)
Updated
Jul 25 closing price
Capitalization
997.68M
Interact to see
Advertisement

CRNX vs ZYME

Header iconCRNX vs ZYME Comparison
Open Charts CRNX vs ZYMEBanner chart's image
Crinetics Pharmaceuticals
Price$30.99
Change+$0.58 (+1.91%)
Volume$737.32K
Capitalization2.9B
Zymeworks
Price$13.33
Change-$0.68 (-4.85%)
Volume$248.4K
Capitalization997.68M
CRNX vs ZYME Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. ZYME commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Hold and ZYME is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (CRNX: $30.99 vs. ZYME: $13.33)
Brand notoriety: CRNX and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 100% vs. ZYME: 55%
Market capitalization -- CRNX: $2.9B vs. ZYME: $997.68M
CRNX [@Biotechnology] is valued at $2.9B. ZYME’s [@Biotechnology] market capitalization is $997.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, ZYME is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 4 TA indicator(s) are bullish while ZYME’s TA Score has 2 bullish TA indicator(s).

  • CRNX’s TA Score: 4 bullish, 6 bearish.
  • ZYME’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, CRNX is a better buy in the short-term than ZYME.

Price Growth

CRNX (@Biotechnology) experienced а -0.39% price change this week, while ZYME (@Biotechnology) price change was -6.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

CRNX is expected to report earnings on Nov 06, 2025.

ZYME is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($2.9B) has a higher market cap than ZYME($998M). ZYME YTD gains are higher at: -8.948 vs. CRNX (-39.390). ZYME has higher annual earnings (EBITDA): -95.45M vs. CRNX (-373.49M). CRNX has more cash in the bank: 1.27B vs. ZYME (265M). ZYME has less debt than CRNX: ZYME (18.5M) vs CRNX (50.8M). ZYME has higher revenues than CRNX: ZYME (93.4M) vs CRNX (760K).
CRNXZYMECRNX / ZYME
Capitalization2.9B998M291%
EBITDA-373.49M-95.45M391%
Gain YTD-39.390-8.948440%
P/E RatioN/AN/A-
Revenue760K93.4M1%
Total Cash1.27B265M481%
Total Debt50.8M18.5M275%
FUNDAMENTALS RATINGS
CRNX vs ZYME: Fundamental Ratings
CRNX
ZYME
OUTLOOK RATING
1..100
5484
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
44
Fair valued
PROFIT vs RISK RATING
1..100
70100
SMR RATING
1..100
9495
PRICE GROWTH RATING
1..100
8346
P/E GROWTH RATING
1..100
10068
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZYME's Valuation (44) in the Pharmaceuticals Major industry is somewhat better than the same rating for CRNX (91). This means that ZYME’s stock grew somewhat faster than CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (70) in the Pharmaceuticals Major industry is in the same range as ZYME (100). This means that CRNX’s stock grew similarly to ZYME’s over the last 12 months.

CRNX's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as ZYME (95). This means that CRNX’s stock grew similarly to ZYME’s over the last 12 months.

ZYME's Price Growth Rating (46) in the Pharmaceuticals Major industry is somewhat better than the same rating for CRNX (83). This means that ZYME’s stock grew somewhat faster than CRNX’s over the last 12 months.

ZYME's P/E Growth Rating (68) in the Pharmaceuticals Major industry is in the same range as CRNX (100). This means that ZYME’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXZYME
RSI
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
73%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
76%
MACD
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 10 days ago
76%
Bullish Trend 10 days ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
78%
Bearish Trend 1 day ago
82%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NEAGX52.66N/A
N/A
Needham Aggressive Growth Retail
OBEGX32.74N/A
N/A
Oberweis Global Opportunities Investor
FMDCX15.80N/A
N/A
Federated Hermes Mid-Cap Index Svc
RIGBX43.32-0.19
-0.44%
American Funds Intl Gr and Inc R2
CIVAX19.63-0.15
-0.76%
American Funds International Vntg 529-A

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+1.91%
XNCR - CRNX
61%
Loosely correlated
N/A
IDYA - CRNX
58%
Loosely correlated
-1.33%
TRDA - CRNX
57%
Loosely correlated
+2.35%
RVMD - CRNX
56%
Loosely correlated
+1.84%
KRYS - CRNX
55%
Loosely correlated
-1.59%
More